The STEP 5 data suggests that ongoing administration is necessary to maintain results, as participants who discontinued semaglutide in the STEP 1 extension study regained approximately two-thirds of the weight they had lost within one year of stopping
From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus
As a GLP-1 receptor agonist, semaglutide mimics the incretin hormone GLP-1, increasing insulin release, decreasing glucagon levels, and slowing gastric emptying
In simple terms: semaglutide targets one hormone that makes you feel full and controls blood sugar, while tirzepatide targets two hormones, potentially offering even greater weight loss and improved metabolism
Always follow the professional recommendations from your provider to avoid issues with improper dosing
This makes the replacement process faster